Genetic polymorphism analysis of the drug-metabolizing enzyme CYP1A2 in a Uyghur Chinese population: a pilot study

References

• Adamec C. (1964). Example of the use of the nonparametric test. Test X2 for comparison of 2 independent examples. Ceskoslovenské Zdravotnictví 12:613
   PubMedGoogle Scholar
• Aklillu E, Carrillo JA, Makonnen E, et al. (2003). Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64:659–69
   PubMed Web of Science ®Google Scholar
• B'Chir F, Pavanello S, Knani J, et al. (2009). CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci 84:779–84
   PubMed Web of Science ®Google Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–5
   PubMed Web of Science ®Google Scholar
• Chida M, Yokoi T, Fukui T, et al. (1999). Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90:899–902
   PubMedGoogle Scholar
• Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. (2010). Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2-163C> a polymorphism. Eur J Clin Pharmacol 66:697–703
   PubMed Web of Science ®Google Scholar
• Ghotbi R, Christensen M, Roh HK, et al. (2007). Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype–phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63:537–46
   PubMed Web of Science ®Google Scholar
• Gunes A, Dahl ML. (2008). Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9:625–37
   PubMed Web of Science ®Google Scholar
• Hamdy SI, Hiratsuka M, Narahara K, et al. (2003). Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 55:321–4
   PubMed Web of Science ®Google Scholar
• Hu M, Yang YL, Fok BS, et al. (2012). Effects ofCYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects. Drug Metab Drug Interact 27:33–9
   PubMedGoogle Scholar
• Kall M, Clausen J. (1995). Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man. Hum Exp Toxicol 14:801–7
   PubMed Web of Science ®Google Scholar
• Larsen JT, Brosen K. (2005). Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. Basic Clin Pharmacol Toxicol 97:141–8
   PubMed Web of Science ®Google Scholar
• Li H, Cho K, Kidd JR, Kidd KK. (2009). Genetic landscape of Eurasia and “admixture” in Uyghurs. Am J Hum Genet 85:934–7
   PubMed Web of Science ®Google Scholar
• Lim JS, Singh O, Ramasamy RD, et al. (2010). Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet 25:616–23
   PubMed Web of Science ®Google Scholar
• Ng PC, Henikoff S. (2002). Accounting for human polymorphisms predicted to affect protein function. Genome Res 12:436–46
   PubMed Web of Science ®Google Scholar
• Ng PC, Henikoff S. (2006). Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61–80
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Okey AB, et al. (2001). Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-> A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 21:603–7
   PubMed Web of Science ®Google Scholar
• Sachse C, Bhambra U, Smith G, et al. (2003). Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55:68–76
   PubMed Web of Science ®Google Scholar
• Sachse C, Brockmller J, Bauer S, Roots I. (1999). Functional significance of aC-> a polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445–9
   PubMed Web of Science ®Google Scholar
• Salameh G, Alhadidi K, Elkhateeb M. (2012). Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol 34:23–33
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23
   PubMed Web of Science ®Google Scholar
• Skarke C, Kirchhof A, Geisslinger G, Lotsch J. (2005). Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. Eur J Clin Pharmacol 61:887–92
   PubMed Web of Science ®Google Scholar
• Song L, Du Q, Jiang X, Wang L. (2014). Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. J Clin Pharm Ther 39:204–9
   PubMed Web of Science ®Google Scholar
• Soyama A, Saito Y, Hanioka N, et al. (2005). Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 20:24–33
   PubMedGoogle Scholar
• Szalai R, Magyari L, Matyas P, et al. (2014). Genetic polymorphisms in promoter and intronic regions of CYP1A2 gene in Roma and Hungarian population samples. Environ Toxicol Pharmacol 38:814–20
   PubMed Web of Science ®Google Scholar
• Tchernitchko D, Rrobreau AM, Lefebvre T, et al. (2012). Comprehensive cytochrome P450 CYP1A2 gene analysis in French Caucasian patients with familial and sporadic porphyria cutanea tarda. Br J Dermatol 166:425–9
   PubMed Web of Science ®Google Scholar
• Thorn CF, Aklillu E, Klein TE, Altman RB. (2012). PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics 22:73–7
   PubMed Web of Science ®Google Scholar
• Uslu A, Ogus C, Ozdemir T, et al. (2010). The effect of CYP1A2 gene polymorphisms on theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. BMB Rep 43:530–4
   PubMed Web of Science ®Google Scholar
• Vistisen K, Poulsen HE, Loft S. (1992). Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 13:1561–8
   PubMed Web of Science ®Google Scholar
• Xu S, Huang W, Qian J, Jin L. (2008). Analysis of genomic admixture in Uyghur and its implication in mapping strategy. Am J Hum Genet 82:883–94
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang WJ, Zhu J, et al. (2012). Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics 13:309–21
   PubMed Web of Science ®Google Scholar
• Zhou H, Josephy PD, Kim D, Guengerich FP. (2004). Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch Biochem Biophys 422:23–30
   PubMed Web of Science ®Google Scholar
• Zhou SF, Yang LP, Zhou ZW, et al. (2009). Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 11:481–94
   PubMed Web of Science ®Google Scholar